Neumora Therapeutics Inc (NASDAQ: NMRA) on Monday, soared 5.33% from the previous trading day, before settling in for the closing price of $10.32. Within the past 52 weeks, NMRA’s price has moved between $8.33 and $21.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 55.65%. With a float of $55.35 million, this company’s outstanding shares have now reached $160.48 million.
In an organization with 124 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Neumora Therapeutics Inc (NMRA) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Neumora Therapeutics Inc is 65.74%, while institutional ownership is 29.79%. The most recent insider transaction that took place on Oct 18 ’24, was worth 239,319. In this transaction Director of this company sold 14,049 shares at a rate of $17.03, taking the stock ownership to the 20,100 shares. Before that another transaction happened on Oct 17 ’24, when Company’s Director sold 7,739 for $17.01, making the entire transaction worth $131,643. This insider now owns 20,100 shares in total.
Neumora Therapeutics Inc (NMRA) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 55.65% per share during the next fiscal year.
Neumora Therapeutics Inc (NASDAQ: NMRA) Trading Performance Indicators
Neumora Therapeutics Inc (NMRA) is currently performing well based on its current performance indicators. A quick ratio of 10.98 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.85, a number that is poised to hit -0.44 in the next quarter and is forecasted to reach -1.64 in one year’s time.
Technical Analysis of Neumora Therapeutics Inc (NMRA)
Let’s dig in a bit further. During the last 5-days, its volume was 0.83 million. That was better than the volume of 0.75 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 79.59%. Additionally, its Average True Range was 0.69.
During the past 100 days, Neumora Therapeutics Inc’s (NMRA) raw stochastic average was set at 19.50%, which indicates a significant decrease from 92.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 36.69% in the past 14 days, which was lower than the 67.60% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.06, while its 200-day Moving Average is $11.74. However, in the short run, Neumora Therapeutics Inc’s stock first resistance to watch stands at $11.17. Second resistance stands at $11.48. The third major resistance level sits at $11.95. If the price goes on to break the first support level at $10.39, it is likely to go to the next support level at $9.92. Assuming the price breaks the second support level, the third support level stands at $9.61.
Neumora Therapeutics Inc (NASDAQ: NMRA) Key Stats
Market capitalization of the company is 1.71 billion based on 161,561K outstanding shares. Right now, sales total 0 K and income totals -235,930 K. The company made 0 K in profit during its latest quarter, and -72,550 K in sales during its previous quarter.
